Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation
Authors
Keywords
-
Journal
PATHOLOGY
Volume 53, Issue 2, Pages 141-156
Publisher
Elsevier BV
Online
2020-12-31
DOI
10.1016/j.pathol.2020.10.007
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Biomarkers for immunotherapy response in head and neck cancer
- (2020) Niki Gavrielatou et al. CANCER TREATMENT REVIEWS
- Cytology for PD-L1 testing: A systematic review
- (2020) John R. Gosney et al. LUNG CANCER
- Pembrolizumab for Early Triple-Negative Breast Cancer
- (2020) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-Ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma
- (2020) Hao Chen et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Checkpoint inhibitors (CPI) and autoimmune chronic inflammatory diseases (ACIDs): tolerance and loss of tolerance in the occurrence of immuno-rheumatologic manifestations
- (2020) Elisa Gremese et al. CLINICAL IMMUNOLOGY
- Canadian Multicenter Project on Standardization of Programmed Death-Ligand 1 Immunohistochemistry 22C3 Laboratory-Developed Tests for Pembrolizumab Therapy in NSCLC
- (2020) Emina Torlakovic et al. Journal of Thoracic Oncology
- Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer
- (2020) Emily S. Reisenbichler et al. MODERN PATHOLOGY
- The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee
- (2020) Lynette M. Sholl et al. Journal of Thoracic Oncology
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- PD-1/PD-L1 Inhibitors in Cervical Cancer
- (2019) Yuncong Liu et al. Frontiers in Pharmacology
- An update of knowledge on PD-L1 in head and neck cancers: physiologic, prognostic and therapeutic perspectives
- (2019) Daniel Lenouvel et al. ORAL DISEASES
- Genomic correlates of response to immune checkpoint blockade
- (2019) Tanya E. Keenan et al. NATURE MEDICINE
- Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases
- (2019) Dennis P. O’Malley et al. MODERN PATHOLOGY
- Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
- (2019) Yung-Jue Bang et al. Gastric Cancer
- PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology
- (2019) Henning Reis et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell PD-L1 Expression in Patients with Advanced NCSLC Screened for the ATLANTIC Study
- (2019) Anne-Marie Boothman et al. Journal of Thoracic Oncology
- Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
- (2019) Filipe Martins et al. Nature Reviews Clinical Oncology
- Significant association of PD-L1 expression with human papillomavirus positivity and its prognostic impact in oropharyngeal cancer
- (2019) Angela M. Hong et al. ORAL ONCOLOGY
- Preanalytics and Precision Pathology: Pathology Practices to Ensure Molecular Integrity of Cancer Patient Biospecimens for Precision Medicine
- (2019) Carolyn C. Compton et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- A minimum of 100 tumor cells in a single biopsy sample is required to assess programmed cell death ligand 1 expression in predicting patient response to nivolumab treatment in non-squamous non-small cell lung carcinoma
- (2019) Tomoyuki Naito et al. Journal of Thoracic Oncology
- Impact of delayed and prolonged fixation on the evaluation of immunohistochemical staining on lung carcinoma resection specimen
- (2019) Maartje van Seijen et al. VIRCHOWS ARCHIV
- T Cell Dysfunction in Cancer Immunity and Immunotherapy
- (2019) Anliang Xia et al. Frontiers in Immunology
- Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non–small-cell lung cancer: The global, multicenter EXPRESS study
- (2019) M. Dietel et al. LUNG CANCER
- “Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy
- (2019) Emina Torlakovic et al. MODERN PATHOLOGY
- Comparison of PD-L1 expression between paired cytologic and histologic specimens from non-small cell lung cancer patients
- (2019) C. Kuempers et al. VIRCHOWS ARCHIV
- Effects of Decalcifying Agents of Variable Duration on PD-L1 Immunohistochemistry
- (2019) Amanda L Strickland et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- P2.09-17 Real-World Concordance Across Pathologists for PD-L1 Scoring in Non-Small Cell Lung Cancer: Results from a Large Nationwide Initiative
- (2019) J. Adam et al. Journal of Thoracic Oncology
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- (2019) Barbara Burtness et al. LANCET
- PD-L1 assessment in urothelial carcinoma: a practical approach
- (2019) Markus Eckstein et al. Annals of Translational Medicine
- Adequate tumour cellularity is essential for accurate PD ‐L1 immunohistochemistry assessment on cytology cell‐block specimens
- (2019) Shona Hendry et al. CYTOPATHOLOGY
- PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee
- (2019) Sylvie Lantuejoul et al. Journal of Thoracic Oncology
- Concordance of PD‐1 and PD‐L1 (B7‐H1) in paired primary and metastatic clear cell renal cell carcinoma
- (2019) Jeanette E. Eckel‐Passow et al. Cancer Medicine
- PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma
- (2018) Anjelica Hodgson et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer
- (2018) J Adam et al. ANNALS OF ONCOLOGY
- Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society
- (2018) Erik Thunnissen et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer
- (2018) Karina Kulangara et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- PD-L1 immunoexpression in matched biopsy and liquid based cytology samples of advanced stage non-small cell lung carcinomas
- (2018) Deepali Jain et al. CYTOPATHOLOGY
- PD-L1 Expression Heterogeneity in Non–Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections
- (2018) Enrico Munari et al. Journal of Thoracic Oncology
- Updated efficacy analysis including secondary population results for OAK: a randomized phase III study of atezolizumab vs docetaxel in patients with previously treated advanced non-small cell lung cancer
- (2018) L. Fehrenbacher et al. Journal of Thoracic Oncology
- PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project
- (2018) Ming Sound Tsao et al. Journal of Thoracic Oncology
- Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer
- (2018) Shona Hendry et al. Journal of Thoracic Oncology
- Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms
- (2018) Christina Koppel et al. MODERN PATHOLOGY
- Efficacy and safety of nivolumab (Nivo) in patients (pts) with advanced or recurrent uterine cervical or corpus cancers.
- (2018) Kosei Hasegawa et al. JOURNAL OF CLINICAL ONCOLOGY
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- Relative Efficacy of Checkpoint Inhibitors for Advanced NSCLC According to Programmed Death-Ligand-1 Expression: A Systematic Review and Network Meta-Analysis
- (2018) Jinchul Kim et al. Scientific Reports
- Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
- (2018) Leisha A. Emens et al. JAMA Oncology
- How to Validate Predictive Immunohistochemistry Testing in Pathology? A Practical Approach Exploiting the Heterogeneity of Programmed Death Ligand-1 Present in Non–Small Cell Lung Cancer
- (2018) Erik Thunnissen ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study
- (2018) Andrea Necchi et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Der prädiktive Wert der PD-L1-Diagnostik
- (2018) H.-U. Schildhaus PATHOLOGE
- Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus
- (2018) Manish A. Shah et al. JAMA Oncology
- Analysis of PD-L1 expression in trophoblastic tissues and tumors
- (2018) Bingjian Lu et al. HUMAN PATHOLOGY
- PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
- (2017) Fred R. Hirsch et al. Journal of Thoracic Oncology
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- De-novo and acquired resistance to immune checkpoint targeting
- (2017) Nicholas L Syn et al. LANCET ONCOLOGY
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
- (2017) Arjun V Balar et al. LANCET ONCOLOGY
- PD-L1 IHC in NSCLC with a global and methodological perspective
- (2017) Erik Thunnissen et al. LUNG CANCER
- Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression
- (2017) Maria Tretiakova et al. MODERN PATHOLOGY
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Accurate PD-L1 Protocols for Non–Small Cell Lung Cancer can be Developed for Automated Staining Platforms With Clone 22C3
- (2017) Rasmus Røge et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx
- (2017) Birgit G. Skov et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer
- (2017) David L. Rimm et al. JAMA Oncology
- PD-1/PD-L and autoimmunity: A growing relationship
- (2016) Mohammad Reza Zamani et al. CELLULAR IMMUNOLOGY
- Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma
- (2016) Marlon C. Rebelatto et al. Diagnostic Pathology
- A Harmonization Study for the Use of 22C3 PD-L1 Immunohistochemical Staining on Ventana’s Platform
- (2016) Tzahi Neuman et al. Journal of Thoracic Oncology
- Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer
- (2016) Jamaal A Rehman et al. MODERN PATHOLOGY
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype
- (2016) Laveniya Satgunaseelan et al. PATHOLOGY
- PD-L1 expression in tonsillar cancer is associated with human papillomavirus positivity and improved survival: implications for anti-PD1 clinical trials
- (2016) Angela M Hong et al. Oncotarget
- Fading With Time of PD-L1 Immunoreactivity in Non–Small Cells Lung Cancer Tissues
- (2016) Francesca Giunchi et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
- (2016) Joseph McLaughlin et al. JAMA Oncology
- Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer
- (2016) Jin Sheng et al. Scientific Reports
- Immunohistochemistry should undergo robust validation equivalent to that of molecular diagnostics
- (2015) Kelly Elliott et al. JOURNAL OF CLINICAL PATHOLOGY
- Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer
- (2015) Antonio Calles et al. Journal of Thoracic Oncology
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Standardization of Positive Controls in Diagnostic Immunohistochemistry
- (2015) Emina E. Torlakovic et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- A Review of Preanalytical Factors Affecting Molecular, Protein, and Morphological Analysis of Formalin-Fixed, Paraffin-Embedded (FFPE) Tissue: How Well Do You Know Your FFPE Specimen?
- (2014) B. Paige Bass et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Principles of Analytic Validation of Immunohistochemical Assays: Guideline From the College of American Pathologists Pathology and Laboratory Quality Center
- (2014) Patrick L. Fitzgibbons et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs
- (2014) Lei Lu et al. Journal of Translational Medicine
- PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials
- (2014) Jason Madore et al. Pigment Cell & Melanoma Research
- Data Set for Pathology Reporting of Cutaneous Invasive Melanoma
- (2013) Richard A. Scolyer et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
- (2012) D. S. Chen et al. CLINICAL CANCER RESEARCH
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
- (2012) Suzanne L Topalian et al. CURRENT OPINION IN IMMUNOLOGY
- Endobronchial ultrasound-guided transbronchial needle aspiration cytology: a state of the art review
- (2010) S. E. H. Cameron et al. CYTOPATHOLOGY
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now